How big is Elutia, Inc.?

As of Jun 18, Elutia, Inc. has a market capitalization of 72.77 million and reported net sales of 23.71 million with a net profit of -40.28 million over the latest four quarters. As of Dec 24, shareholder's funds were -46.26 million and total assets were 36.13 million.

As of Jun 18, Elutia, Inc. has a market capitalization of 72.77 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 23.71 million, while the sum of net profit for the same period is -40.28 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of -46.26 million and total assets of 36.13 million.

What does Elutia, Inc. do?

Elutia, Inc. is a regenerative medicine company focused on developing products for surgical patients, particularly those with implantable medical devices. As of March 2025, it reported net sales of $6 million and a net loss of $4 million, with a market cap of $72.77 million.

Overview: <BR>Elutia, Inc. is a commercial-stage regenerative medicine company focused on developing products for patients undergoing surgery, particularly those receiving implantable medical devices, and operates within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 72.77 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.48 <BR>Return on Equity: 76.88% <BR>Price to Book: -2.00 <BR><BR>Contact Details: <BR>Address: 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD: 20904 <BR>Tel: 1 240 2471143 <BR>Fax: 1 510 3079896 <BR>Website: http://aziyo.com/

Should I buy, sell or hold Elutia, Inc.?

Who are in the management team of Elutia, Inc.?

As of March 2022, the management team of Elutia, Inc. includes Mr. Kevin Rakin as Chairman of the Board and Mr. Ron Lloyd as President, CEO, and Director.

As of March 2022, the management team of Elutia, Inc. includes Mr. Kevin Rakin, who serves as the Chairman of the Board, and Mr. Ron Lloyd, who holds the positions of President, Chief Executive Officer, and Director.

Is Elutia, Inc. overvalued or undervalued?

Elutia, Inc. is considered overvalued and risky due to negative valuation ratios and a year-to-date return of -71.12%, significantly underperforming compared to the S&P 500's gain of 12.22%.

As of 1 March 2021, Elutia, Inc. has moved from a grade of does not qualify to risky, indicating an increased perception of potential investment risk. The company appears to be overvalued based on its negative valuation ratios, including a Price to Book Value of -2.14, an EV to EBIT of -4.17, and an EV to EBITDA of -4.91. These metrics suggest that the company is struggling financially, particularly in comparison to its peers, such as Catalyst Biosciences, Inc. with a P/E of 110.04 and Pluri, Inc. with a P/E of -1.72.<BR><BR>Elutia's recent stock performance has been significantly poor, with a year-to-date return of -71.12% compared to the S&P 500's gain of 12.22%. This stark contrast reinforces the notion that Elutia, Inc. is overvalued in its current state.

Is Elutia, Inc. technically bullish or bearish?

As of September 9, 2025, Elutia, Inc. is in a bearish trend, indicated by negative technical indicators and a year-to-date return of -71.12%, significantly underperforming the S&P 500's 12.22%.

As of 9 September 2025, the technical trend for Elutia, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including bearish MACD readings on both the weekly and monthly time frames, bearish Bollinger Bands, and bearish moving averages on the daily chart. Additionally, Dow Theory indicates a bearish trend on both weekly and monthly scales. The KST shows a mildly bullish signal on the weekly but is bearish monthly, while OBV is mildly bearish on both time frames. <BR><BR>Elutia, Inc. has significantly underperformed compared to the S&P 500, with a year-to-date return of -71.12% versus the S&P 500's 12.22%, and a one-year return of -72.02% compared to 17.14% for the index.